ESR1 and breast cancer: However, co-incident mutation of ATR and TP53 is 12-fold enriched in metastatic ER+/HER2− breast cancer over primary disease (P = 0.0002) and twofold enriched over TNBC (P = 0.02) (Fig. 7A).